
Sarepta Therapeutics (SRPT) Stock Forecast & Price Target
Sarepta Therapeutics (SRPT) Analyst Ratings
Bulls say
Sarepta Therapeutics Inc. exhibits a strong potential for growth, demonstrated by a consistent number of start forms, which management believes could translate into annual sales surpassing the $500 million mark. The preliminary net revenue for PMO products of $259.2 million in Q4 2025 reflects a 9% increase from the previous quarter, indicating stable adoption and resilient payer coverage despite ongoing clinical evaluations. Additionally, anticipated initial data from the Phase 1/2 programs for FSHD and DM1 may further enhance the company’s outlook, as competitive siRNA profiles could foster additional revenue opportunities not currently reflected in valuation models.
Bears say
Sarepta Therapeutics Inc. reported a preliminary fourth quarter 2025 Elevidys net revenue of $110.4 million, which fell short of the $117 million consensus expectation and highlighted revenue volatility, particularly due to the deferral of treatments for six patients. Despite management's optimism regarding an annual sales floor of $500 million and plans to double the salesforce in 2026, concerns linger about the company's reliance on a small patient base, which could significantly impact quarterly revenue figures. Additionally, there are doubts about Elevidys's true efficacy and safety profile in the Duchenne muscular dystrophy population, alongside growing competition from next-generation therapies, which could pressure future demand.
This aggregate rating is based on analysts' research of Sarepta Therapeutics and is not a guaranteed prediction by Public.com or investment advice.
Sarepta Therapeutics (SRPT) Analyst Forecast & Price Prediction
Start investing in Sarepta Therapeutics (SRPT)
Order type
Buy in
Order amount
Est. shares
0 shares